Epigenetic clock as the new hand of time for lung cancer in never smokers.
Christiani DC.
Thorax. 2024 Jul 16. 79(8):697. PMID: 38702189
Faculty Affiliate in the Department of Epidemiology
Epidemiology
Harvard T.H. Chan School of Public Health
Professor of Medicine
Medicine-Massachusetts General Hospital
Harvard Medical School
David Christiani, MD, MPH, MS, is the Elkan Blout Professor of Environmental Genetics with the Harvard TH Chan School of Public Health and Professor of Medicine at Harvard Medical School. He earned his MD in 1976 from Tufts University, and an MS and MPH from the Harvard School of Public Health. He did his post-graduate medical training at Boston City Hospital and the Massachusetts General Hospital in Boston.
Professor Christiani’s major research interest lies in the interaction between human genes and the environment. In the emerging field of molecular epidemiology, he studies the impact of humans’ exposure to pollutants on health, as well as the how genetic and acquired susceptibility to these diseases along with environmental exposures can lead to acute and chronic pulmonary and cardiovascular disease. He is also developing new methods for assessing health effects after exposure to pollutants and has is very active in environmental and occupational health studies internationally.
His global work has taken place in Asia, Africa, and North America where Dr. Christiani and his wide network of collaborators are studying of the reproductive effects of exposure to chemicals, in China; arsenic exposure and bladder and skin cancer, in Taiwan and Bangladesh; exposure to indoor combustion products in respiratory disease in Central America; petrochemical exposures, brain tumors, and leukemia in Taiwan; and the molecular epidemiology of esphageal cancer in Africa. Preventing these diseases is an ultimate goal.
Professor Christiani has developed biologic markers useful for examining pollutant-induced diseases such as lung cancer, bladder cancer, skin cancer, and upper-respiratory-tract inflammation. He led a large molecular and genetic analysis of lung cancer, looking at genetic factors that make people susceptibility to lung cancer and help predict the outcome of treatment. He has also led studies of the acute respiratory effects of toxins in the particles produced by coal-burning power plants. This study is also evaluating molecular markers in nasal and lung fluids of exposed and unexposed workers. With collaborators at the Mass. General Hospital, Professor Christiani isl examining the role of genetic susceptibility in acute respiratory failure (ARDS), as well as biomarkers predictive of outcome and survival for this disorder.
Christiani oversees a landmark 40-year-long study of non-smoking relatied chronic respiratory disease in cotton-textile workers in Shanghai, China. This study has determined the rate of loss in lung function among dust and endotoxin-exposed workers and uses molecular biology’s tools to evaluate the relationship between exposure to endotoxins produced by bacteria in cotton and acute and chronic lung disease.
Since 1992, Dr. Christiani has led the NCI-funded Boston Lung Cancer Study which has focused on assessing markers of exposure, susceptibilty, and outcomes in lung cancer. He co-led the Lung Program of the Dana-Farber/Harvard Cancer Institute for 20 years. In 2012, President Obama appointed him to a 7 year term on the National Cancer Advisory Board.
MD, 1976
Tufts University, Medford, Massachusetts
MPH, 1980
Harvard School of Public Health, Boston, Massachusetts
MS, 1981
Harvard School of Public Health, Boston, Massachusetts
Christiani DC.
Thorax. 2024 Jul 16. 79(8):697. PMID: 38702189
Wang X, Hou K, Ricciuti B, Alessi JV, Li X, Pecci F, Dey R, Luo J, Awad MM, Gusev A, Lin X, Johnson BE, Christiani DC.
HGG Adv. 2024 Jun 19. 5(3):100320. PMID: 38902927
Shen H, Zheng R, Du M, Christiani DC.
Thorax. 2024 Jun 14. 79(7):680-691. PMID: 38631896
Wei CF, Mukherjee SK, Ekramullah SM, Arman DM, Islam MJ, Azim M, Rahman A, Rahman MN, Ziauddin M, Tindula G, Suchanda HS, Gomberg DF, Weisskopf MG, Liang L, Warf BC, Christiani DC, Mazumdar M, Wei CF, Mukherjee SK, Ekramullah SM, Arman DM, Islam MJ, Azim M, Rahman A, Rahman MN, Ziauddin M, Tindula G, Suchanda HS, Gomberg DF, Weisskopf MG, Liang L, Warf BC, Christiani DC, Mazumdar M, Wei CF, Mukherjee SK, Ekramullah SM, Arman DM, Islam MJ, Azim M, Rahman A, Rahman MN, Ziauddin M, Tindula G, Suchanda HS, Gomberg DF, Weisskopf MG, Liang L, Warf BC, Christiani DC, Mazumdar M.
Environ Health. 2024 Jun 03. 23(1):51. PMID: 38831396
Chen YH, Wei CF, Cheng YY, Mita C, Hoang CLD, Lin CK, Chang YT, Christiani DC.
Environ Res. 2024 Jul 01. 252(Pt 1):118745. PMID: 38527716
Li Y, Xiao X, Li J, Han Y, Cheng C, Fernandes GF, Slewitzke SE, Rosenberg SM, Zhu M, Byun J, Bossé Y, McKay JD, Albanes D, Lam S, Tardon A, Chen C, Bojesen SE, Landi MT, Johansson M, Risch A, Bickeböller H, Wichmann HE, Christiani DC, Rennert G, Arnold SM, Goodman GE, Field JK, Davies MPA, Shete S, Marchand LL, Liu G, Hung RJ, Andrew AS, Kiemeney LA, Sun R, Zienolddiny S, Grankvist K, Johansson M, Caporaso NE, Cox A, Hong YC, Lazarus P, Schabath MB, Aldrich MC, Schwartz AG, Gorlov I, Purrington KS, Yang P, Liu Y, Bailey-Wilson JE, Pinney SM, Mandal D, Willey JC, Gaba C, Brennan P, Xia J, Shen H, Amos CI.
Cancer Epidemiol Biomarkers Prev. 2024 03 01. 33(3):389-399. PMID: 38180474
Wei CF, Mukherjee SK, Ekramullah SM, Arman DM, Islam MJ, Azim M, Rahman A, Rahman MN, Ziauddin M, Tindula G, Suchanda HS, Gomberg DF, Weisskopf MG, Liang L, Warf BC, Christiani DC, Mazumdar M.
Res Sq. 2024 Feb 29. PMID: 38464105
Du M, Xin J, Zheng R, Yuan Q, Wang Z, Liu H, Liu H, Cai G, Albanes D, Lam S, Tardon A, Chen C, Bojesen SE, Landi MT, Johansson M, Risch A, Bickeböller H, Wichmann HE, Rennert G, Arnold S, Brennan P, Field JK, Shete SS, Le Marchand L, Liu G, Andrew AS, Kiemeney LA, Zienolddiny S, Grankvist K, Johansson M, Caporaso NE, Cox A, Hong YC, Yuan JM, Schabath MB, Aldrich MC, Wang M, Shen H, Chen F, Zhang Z, Hung RJ, Amos CI, Wei Q, Lazarus P, Christiani DC.
Cancer Res. 2024 02 15. 84(4):616-625. PMID: 38117513
Wang X, Zhang Z, Ding Y, Chen T, Mucci L, Albanes D, Landi MT, Caporaso NE, Lam S, Tardon A, Chen C, Bojesen SE, Johansson M, Risch A, Bickeböller H, Wichmann HE, Rennert G, Arnold S, Brennan P, McKay JD, Field JK, Shete SS, Le Marchand L, Liu G, Andrew AS, Kiemeney LA, Zienolddiny-Narui S, Behndig A, Johansson M, Cox A, Lazarus P, Schabath MB, Aldrich MC, Hung RJ, Amos CI, Lin X, Christiani DC.
Genome Med. 2024 02 05. 16(1):22. PMID: 38317189
Zhu M, Lv J, Huang Y, Ma H, Li N, Wei X, Ji M, Ma Z, Song C, Wang C, Dai J, Tan F, Guo Y, Walters R, Millwood IY, Hung RJ, Christiani DC, Yu C, Jin G, Chen Z, Wei Q, Amos CI, Hu Z, Li L, Shen H.
Int J Epidemiol. 2023 Dec 25. 52(6):1815-1825. PMID: 37676847
Quitting smoking early was associated with higher survival rates following a lung cancer diagnosis, according to a new study led by researchers at Harvard Chan School. Compared to those who never smoked and were being treated for non-small…
A study that looked at four patients with chronic lung disease found that e-cigarette use was the most likely cause.
Three Harvard Chan School experts weigh in on the FDA’s decision to authorize a set of three e-cigarette products for sale in the U.S. for the first time.
Knowing the current and previous smoking habits of patients with metastatic non-small cell lung cancer (NSCLC) could allow clinicians to make better informed treatment decisions, according to new research led by Harvard T.H. Chan School of Public Health.…
The amount of tobacco a person with non-small cell lung cancer (NSCLC) consumes is associated with the type and amount of genetic mutations found in their tumors, according to new research led by Harvard T.H. Chan School of…